Granules India is currently trading at RS 551.15, up by 5.15 points or 0.94% from its previous closing price of RS 546.00 on the BSE.

The stock opened at RS 544.65 and has touched an intraday high of RS 555.75 and a low of RS 543.00. So far, a total of 16,444 shares have been traded on the counter.

The BSE Group ‘A’ stock with a face value of RS 1 has recorded a 52-week high of RS 627.45 on 03-Dec-2024 and a 52-week low of RS 412.05 on 07-Apr-2025.

During the last one week, the stock has touched a high of RS 555.75 and a low of RS 530.00. The current market capitalization of the company stands at RS 13,374.69 crore.

Promoters hold 38.82% stake in the company, while institutional and non-institutional investors hold 32.01% and 29.17% respectively.

Granules India’s wholly owned foreign subsidiary — M/s. Granules Pharmaceuticals, Inc., has incorporated a new Wholly Owned Subsidiary, named ‘Granules Pharmaceuticals Canada, Inc.’ in Canada on November 26, 2025. Granules Pharmaceuticals, Inc. will hold 100% equity in the newly formed subsidiary, which has not yet commenced business operations.

Granules India is a manufacturer and supplier of pharmaceutical products, including Active Pharmaceutical Ingredients (API), tablets, caplets, rapid release formulations, Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FDs).